Somatic Disease/Germline Comparator Exome (SDGC) Provider Guide



Introduction to Somatic Disease/Germline Comparator Exome (SDGC) Testing

The Steve and Cindy Rasmussen Institute for Genomic Medicine (IGM) Clinical Laboratory at Nationwide Children's Hospital now offers Somatic Disease/ Germline Comparator Exome (Test Code: SDGC) testing for patients with known or suspected cancer, hematologic disease or somatic disorders.

Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis and medical management, helping providers make treatment decisions and evaluate eligibility for targeted therapies and clinical trials. SDGC testing can also identify germline disease predisposition.

This clinical assay returns information on small variants (single-nucleotide variants, small insertion-deletions), copy number variation (CNV), loss of heterozygosity (LOH), and tumor mutational burden (TMB).

The Institute for Genomic Medicine has optimized approaches to specimen processing, sequencing and variant interpretation in the context of pediatric and adult cancer. Our team has analyzed thousands of individuals with cancer through clinical testing, yielding both germline and somatic medically meaningful findings to guide care.

Our expertise in performing clinical molecular characterization assays is nationally recognized, as evidenced by our selection as the testing laboratory for the Molecular Characterization Initiative, a project that aims to collect, analyze and report clinical molecular data to support Children's Oncology Group (COG)affiliated clinicians in choosing the best treatment for each child as part of the National Cancer Institute (NCI) Childhood Cancer Data Initiative (CCDI).

The IGM Clinical Laboratory is accredited under the College of American Pathologists Laboratory Accreditation Program and certified by CLIA (Clinical Laboratory Improvement Amendments) for clinical testing.



Submission Requirements

DISEASE-INVOLVED AND GERMLINE SAMPLES

This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. Each submitted sample must be labeled with the full patient's name and at least one other unique patient identifier (i.e. DOB, MRN). For a complete list of genes analyzed, please see our website at https://www.testmenu.com/nationwidechildrens

Disease-Involved Sample(s)	Germline Sample
 <i>Tumor percentage for malignant conditions:</i> The disease-involved sample must contain a minimum of 20% tumor or blast content for tumor mutational burden, single-nucleotide and small insertion-deletion variant resolution, and optimally, a minimum of 60% tumor or blast content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH if the submitted specimen contains less than 60% disease-content. In some contexts, the ability to report TMB may be tumor specimen dependent. Please contact the laboratory for further information. <i>Specimen types:</i> One of the following types of specimens is required: Frozen tissue (30-50 mg). Fresh tissue (30-50 mg). FFPE tissue block. 10-15 FFPE scrolls (5-10 microns thick) and adjacent H&E slide. Involved bone marrow (4 mL EDTA). FFPE specimens processed using strong acid decalcification are not acceptable; EDTA and Formical are accepted. Testing will be attempted on samples not meeting minimal tissue criteria if nucleic acid requirements are met. <i>Disease timepoints:</i> Multiple disease timepoints may be submitted for testing. Additional charges will be applied. 	 Specimen type: One of the following types of specimens is required: Whole blood (4 mL EDTA). (This type is preferred.) Saliva (two collection tubes). Buccal swabs (four swabs). Please contact the laboratory if the patient has a history of allogeneic bone marrow transplantation to discuss options for the comparator normal sample.

REQUISITION

Please complete the Oncology Genetic Test Requisition Form in its entirety.

Prior Authorization/Billing

- For insurance preauthorization for SDGC testing, use CPT codes 81415 and 81416.
- Under billing information, select Institutional Bill and complete send-out laboratory information for billing.

PATHOLOGY REPORT

A pathology report is required for every disease-involved specimen. If multiple disease timepoints are submitted, multiple pathology reports are required.

Submission Checklist

Please ensure all the items below are completed and ready before submission.

✓ Completed	REQUIRED MATERIAL				
	Disease-Involved Sample				
	Germline Sample				
	Requisition				
	Pathology Report (for <u>EVERY</u> disease timepoint)				

Submission Instructions

Once all required materials are gathered and completed, send them through your institution's send-out lab to Nationwide Children's Hospital Laboratory at the address below. Please contact the Institute for Genomic Medicine via phone or email to inform our team about your shipment.

Nationwide Children's Hospital Laboratory 700 Children's Drive Room C1955 Columbus, OH 43205

Email: IGMCytoMGLAccessioning@NationwideChildrens.org Phone: (614) 722-5321

When your child needs a hospital, everything matters."

Oncology Genetic Test Requisition Form

Institute for Genomic Medicine (IGM) Clinical Laboratory Tel: (614) 722-5321 / Fax: (614) 722-5471

Laboratory Client Services Tel: (614) 722-5477 / (800) 934-6575

NationwideChildrens.org/Lab

Ship Samples to: Nationwide Children's Laboratory Services 700 Children's Drive, Room C1955 Columbus, OH 43205 U.S.A.

PATIENT INFORM	IATION (Please Print or	Place II	D Label)					
Last Name			F	irst Name				MI	
Date of Birth (DOB)	Sex Assigne Male Fe	ed at Birth Ge emale Unknown	ender Iden	entity SSN			Patient ID #/ MRN		
Street Address			C	ity		State		Zip	
ORDERING PHYS		ORMATION	Please	Print)					
Ordering Physician Nam			<u>`</u>	REQUIRED)	Fax	k (REQUIRED))	NPI #	
Attending Physician Info Attending Physician Nan		EQUIRED if Orderin	n g Physic Phone	ian is a Tra	inee (e.g. l Fax		llow)	NPI#	
Institution / Practice / Fac	ility Name		л						
Street Address			City S		State		Zip/Postal Code		
Physician Email (REQUI	RED if sendin	g from outside U.S	S.A.)	Б. А.) С			Country (if not U.S.A.)		
Ordering Physican Signa	ature					Date	Date		
ADDITIONAL REP	PORT TO	SENDOUT LA	BORA	FORY (P	lease Pr	int):			
Name				hone		Fax			
ICD-10 / CLINICAI	DIAGNO	SIS /SPECIAL	INSTR	UCTION	S				
ICD-10 Codes (REQUIRE	ED)	Clinical Diagnosi	s (REQUI	RED)				Age of Onset	
Special Instructions / No	otes			Has	-	t had a bone r s - Autologous		ransplant? (REQUIRED) Yes - Allogeneic (donor)	
SAMPLE INFORM	ATION (P	lease List All S	amples	Being Su	ubmitted	with This	Form)		
Please check sample re Each submitted sample mu samples will require a sign Submitted samples will be Bone marrow and Blood Samples must arrive in Tissue samples: Tissue sa from the submitted turn	st be labeled we ed specimen is consumed as r d samples: Col the laboratory crolls must be a	with the name and at dentification waiver a needed to complete llect 4 mL of bone mar within 48 hours fron accompanied by H&E	least one and may re the reques rrow or inv n collection slide. Any h	secondary id sult in delaye sted testing w olved blood s n. H&E slide sub	entifier (e.g ed processin vhich may ro ample into mitted with	g. MRN, DOB, S ng and/or repo esult in deplet EDTA tube. Shi tumor sample	SPID). Ins orting. tion of su ip overnig e must be	ufficiently labeled ubmitted samples. ght at room temperature e from a consecutive cut	
Tumor / Involved Sar Bone marrow Snap-frozen tissue FFPE tissue scrolls <u>a</u>	□ Involve □ OCT-em	d peripheral blood bedded tissue	□ Fr □ FF	/blasts esh tissue FPE tissue b her		Collectio	n Date	Sample Time Point: Diagnosis Relapse Post-Treatment Day 	
 □ Bone marrow □ Snap-frozen tissue □ FFPE tissue scrolls a □ Other 	☐ Periphe ☐ OCT-em and consecut	bedded tissue ively cut H&E slide	□ Fr □ FF □ Ur	esh tissue PE tissue b ninvolved pe	eripheral blo			Sample Time Point: Diagnosis Relapse Post-Treatment Day	
<u>REQUIRED</u> : A copy of t include a preliminary re Failure to provide a fina	port with the	sample submission	on and th	en fax the fi	inalized re	port to 614-7	22-5471	, once available.	



Tel: (800) 934-6575 / NationwideChildrens.org/Lab

BILLING INFORMATION

Patient Name (or place patient ID label)

Last, First _____

DOB or MRN _____

■ INSTITUTIONAL BILL (Please	se Print)			
Contact Name:	Phone		Fax	
Email Address (REQUIRED if sending fron	n outside U.S.A.)			
Institution / Hospital / Laboratory Name				
Street Address				
City	State / Province	Zip Code	Country	
Send a result copy to sending Above Fax number Above Other information:		her Fax/Email		

TEST SELECTION

*Internal pathology review by Nationwide Children's pathologist will be performed on submitted samples to assess for tumor/blast content.

CNS / BRAIN TUMOR
CNS Tumor Classification by Methylation Array [test code: CTCMA]
* <u>At least 60% tumor</u> must be present in the submitted sample (based on internal pathology review).
Snap-frozen tissue is Preferred
SOLID TUMOR
Solid Tumor Fusion Analysis by NGS [test code: TUMFUSN]
Identifies gene fusions for 151 genes (see website for list of all gene partners).

*At least 10% tumor	must be pres	ent in the	submitted Fresh	Snap-frozen	OCT	or Bone marrow	samples
Acrouble 1070 turnor			Submitted resil,	Onup-nozen	<u>, 001, </u>	of Done manow	Sumples

*At least 25% tumor must be present in the submitted FFPE tissue block or FFPE tissue scrolls

(based on internal pathology review). Sample acquisition PRIOR TO receiving treatment is strongly preferred.

SOMATIC DISEASE/GERMLINE COMPARATOR EXOME

□ Somatic Disease/Germline Comparator Exome [test code: SDGC]

Submission of a disease-involved sample AND an unaffected comparator sample is REQUIRED.

*For malignant disease, at least 20% tumor content/blasts must be present in the submitted affected sample for singlenucleotide and small insertion-deletion variant resolution and reporting (based on pathology review).

*For malignant disease, at least 60% tumor content/blasts must be present in the submitted affected sample for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation (based on pathology review). Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content

Checklist of Required Items: Disease-involved sample Unaffected sample



Tel: (800) 934-6575 / NationwideChildrens.org/Lab

Patient Name (or place patient ID label)

Last, First _____

DOB or MRN

Please check sample requirements and exclusions for each test on website Nationwidechildrens.org/Lab.

Ship Samples and Completed Test Requisition Form to:

Nationwide Children's Hospital Laboratory 700 Children's Drive, Room C1955 Columbus, OH 43205 U.S.A.

- Ship samples via Overnight Courier. Samples must arrive at the laboratory within 48 hours. Saturday deliveries accepted. Please check "Saturday Delivery" on shipment label.
- For questions regarding testing, specimen requirements or transport, please call the IGM Clinical Laboratory at (614) 722-5321 or Lab Client Services at (800) 934-6575.

Sample Return Request:

Tissue blocks will be returned after testing is complete if there is remaining sample. Provide return details below:

Ship Back to: Name:	Phone:
Address:	
•	

Contact Us

Steve and Cindy Rasmussen Institute for Genomic Medicine Nationwide Children's Hospital

Phone: (614) 722-5321

Email: IGMCytoMGLAccessioning@NationwideChildrens.org Web: NationwideChildrens.org/Specialties/Institute-for-Genomic-Medicine



